Aligos Therapeutics, Inc.
ALGS
$7.37
-$0.28-3.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 809.97% | -73.13% | -41.61% | -9.05% | -68.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 809.97% | -73.13% | -41.61% | -9.05% | -68.46% |
| Cost of Revenue | 22.65% | 6.28% | 42.70% | -33.76% | -96.68% |
| Gross Profit | 1,032.76% | -9.52% | -49.60% | 35.07% | 98.49% |
| SG&A Expenses | 26.82% | -4.19% | 11.65% | -12.86% | -24.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.19% | 3.73% | 35.99% | -28.91% | -15.10% |
| Operating Income | -39.94% | -6.08% | -40.88% | 29.71% | 12.71% |
| Income Before Tax | -152.68% | 75.83% | -64.24% | -398.63% | 223.80% |
| Income Tax Expenses | 637.21% | 11.11% | -38.46% | -2.12% | 79.17% |
| Earnings from Continuing Operations | -153.47% | 75.80% | -63.75% | -413.44% | 223.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.47% | 75.80% | -63.75% | -413.44% | 223.59% |
| EBIT | -39.94% | -6.08% | -40.88% | 29.71% | 12.71% |
| EBITDA | -39.55% | -6.08% | -41.53% | 30.01% | 12.47% |
| EPS Basic | -143.22% | 85.36% | 0.95% | -289.48% | 191.81% |
| Normalized Basic EPS | -142.58% | 85.38% | 0.66% | -280.51% | 191.96% |
| EPS Diluted | -4.80% | 85.34% | 0.95% | -289.48% | 62.14% |
| Normalized Diluted EPS | -144.11% | 85.38% | 0.66% | -280.75% | 188.78% |
| Average Basic Shares Outstanding | 23.72% | 65.29% | 65.32% | 65.41% | 34.62% |
| Average Diluted Shares Outstanding | 19.44% | 65.29% | 65.32% | 65.20% | 39.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |